KRRO Stock — Korro Bio Inc.: Cash, EV, Pipeline

What they do

We are a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. We are generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient change to a single nucleoside (adenosine to an inosine edit).

Source: 10-K FY2025 via SEC EDGAR

Share price

$14.75

Market cap

$217.2M

Cash

$124.8M

Enterprise value

$92.4M

Balance sheet

Cash	$124.8M
Debt	$0.0M
Net cash	$124.8M
Enterprise value	$92.4M
Basic shares	13.7M shares
Fully diluted shares	20.4M shares
Fully diluted market cap	$300.9M
Cash per share	$9.09
Quarterly burn	$17.0M
Cash runway	8.1 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

14.7M

Pre-funded warrants

3.1M

Options

1.9M

RSUs

0.3M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.3M

FDSO

20.4M

Cap table as of 2026-06-30.

Price history

Loading KRRO daily closes…

Loading price history…

Recently reported

KRRO-121 Phase 1/2 Mixed · 2026-10-05

KRRO-121 · urea cycle disorders, inborn, urea cycle disorders, ornithine transcarbamylase (otc) deficiency

Source release →

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

KRRO-110

Phase 1 · Terminated Modality: RNA editing

Target SERPINA1 transcript

Indications

alpha-1 antitrypsin deficiency (AATD) (Phase 1)

Status note Phase 1/2a REWRITE trial in AATD terminated in Q1 2026 after the trial did not produce positive results; KRRO-110 external R&D expenses fell ~$11.5M in H1 2026 on the termination.

KRRO-111

Preclinical · Active Modality: RNA editing (GalNAc-conjugated)

Target AAT (alpha-1 antitrypsin) protein repair

Indications

alpha-1 antitrypsin deficiency (AATD) (Preclinical)

Status note Development candidate for AATD announced May 2026; preclinical and manufacturing costs underway. Targets repair of the alpha-1 antitrypsin protein.

KRRO-121

Preclinical · Active Modality: RNA editing

Target ammonia clearance

Indications

urea cycle disorders / hyperammonemia (Preclinical)

Status note Hyperammonemia program targeting increased clearance of ammonia in multiple indications; preclinical and manufacturing costs underway.

AMPKγ1 program

Preclinical · Active Modality: RNA editing (GalNAc-conjugated)

Target AMPKγ1 pathway

Indications

liver health / longevity (Preclinical)

Status note Longevity and liver health program targeting activation of the AMPKγ1 pathway. No named candidate disclosed.

TDP-43 program

Preclinical · Active Modality: RNA editing (intrathecal delivery)

Target TDP-43

Indications

amyotrophic lateral sclerosis (ALS) (Preclinical)

Status note ALS program targeting creation of a de novo variant of TDP-43. No named candidate disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	KRRO-121
Lead indication	Urea Cycle Disorders, Inborn
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07773246	Phase 2	Not yet recruiting	Sponsor	KRRO	—	Urea Cycle Disorders, Inborn; Urea Cycle Disorders; Ornithine Transcarbamylase (OTC) Deficiency	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Korro Bio, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	540,054	no change	0.33%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

KRRO — Korro Bio Inc. ☆

What they do

Balance sheet

Share structure

Price history

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

KRRO — Korro Bio Inc.